================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: October 20, 2003
QLT Inc.
-----------------------------------------------------
(Exact name of registrant as specified in its Charter)
British Columbia, Canada 000-17082 N/A
- ------------------------ ------------------------ -------------------
(Jurisdiction of (Commission File Number) (IRS Employer
Incorporation) Identification No.)
QLT Inc.,
887 Great Northern Way,
Vancouver, B.C., CANADA, V5T 4T5
(604) 707-7000
-----------------------------------------------------
(Address, including zip code, and telephone number,
including area code, of principal executive offices)
================================================================================
ITEM 5. OTHER EVENTS
On October 20, 2003, QLT Inc. reported that its alliance partner,
Novartis, announced global Visudyne(R) (verteporfin) sales of
approximately US$89.8 million for the quarter ended September 30,
2003. This represents an increase of 28% over sales in the third
quarter of 2002.
ITEM 7. EXHIBITS
Exhibit
Number Description
- ------- -----------
99.1 Press release dated October 20, 2003
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
QLT Inc.
-------------------------------------
(Registrant)
Date October 20, 2003 /s/ Paul J. Hastings
-------------------- -------------------------------------
(Signature)
President and Chief Executive Officer